The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC
Sai-Hong Ou, MD, PhD, discusses the rapidly evolving landscape of first-line therapy for sensitizing EGFR mutant non-small cell lung cancer, including potential combination therapies and the introduction of new treatment options, such as antibody drug conjugates.
EP: 1.Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC
EP: 2.Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC
EP: 3.Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs
EP: 4.Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC
EP: 5.Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation
EP: 6.Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations
EP: 7.Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC
EP: 8.Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)
EP: 9.EGFR Mutations in Patients With NSCLC
EP: 10.Adverse Effect Management in Non–Small Cell Lung Cancer Treatment
EP: 11.Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC
Now Viewing
EP: 12.The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC
EP: 13.Multidisciplinary Care, Approval Updates, and Future Research in NSCLC
EP: 14.Treatment Approaches for Patients With EGFR-Mutant NSCLC
EP: 15.Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC
EP: 16.Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance
EP: 17.Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations
EP: 18.Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations
EP: 19.The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations
EP: 20.Unmet Needs and Future Perspectives in NSCLC Treatment
EP: 21.New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies
Recent Videos
Related Content
Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS
August 14th 2025Article
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
